Key Inclusion Criteria:~Core Treatment Period:~* Participant was participating in an aducanumab clinical study
at the time of the announcement of early termination (feeder studies).~* Has one care partner who, in the
Investigator's opinion, has adequate contact with the participant as to be able to provide accurate information
about the participant's cognitive and functional abilities.~LTE Treatment Period:~* Participant must have
completed the Core study period (Week 102) and adequately tolerated 10 mg/kg of aducanumab during the Core
study period in the opinion of the Investigator.~* Has one informant/care partner who, in the Investigator's
opinion, has frequent and sufficient contact with the participant as to be able to provide accurate information
about the participant's cognitive and functional abilities.~Key
